Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma

by Roberto W. Dal Negro, Luca Bonadiman, Paola Turco
Published 2018-09-01

Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma

by Roberto W. Dal Negro, Luca Bonadiman, Paola Turco
Published 2018-06-01

Correction to: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate a...

by Roberto W. Dal Negro, Luca Bonadiman, Paola Turco
Published 2018-07-01

Clinical and pharmacoeconomic profile of COPD patients with FEV1 50—60% predicted: pilot study on the impact of the extended indication of ICS/LABA

by Roberto Walter Dal Negro, Luca Bonadiman, Claudio Turati, Paola Turco
Published 2009-04-01

The impact of LABA+ICS fixed combinations on morbidity and economic burden of COPD in Italy: a six-year observational study

by Roberto Dal Negro, Luca Bonadiman, Silvia Tognella, Claudio Micheletto, Paola Turco
Published 2011-04-01

Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a be...

by Roberto W. Dal Negro, Pietro Longo, Orestepaolo Villanis Ziani, Luca Bonadiman, Paola Turco
Published 2017-06-01